Thomas F. Lüscher

Oct 14, 2024 | nature.com | Faiez Zannad |C. Michael Gibson |Cecilia Linde |Thomas F. Luscher |Thomas F. Lüscher |Richard Mindham | +3 more

AbstractCardiovascular clinical trials continue to under-represent children, older adults, females and people from ethnic minority groups relative to population disease distribution. Here we describe strategies to foster trial representativeness, with proposed actions at the levels of trial funding, design, conduct and dissemination.